Subgrouping and outcome prediction of diffuse large B-cell lymphoma by immunohistochemistry

Chinese Journal of Pathology

Volumn 36, Issue 10, 2007, Pages 654-659

  Ye, Zi Yin ^a   Cao, Ya Bing ^b   Lin, Tong Yu ^b   Lin, Han Liang ^b  

^a SUN YAT SEN UNIVERSITY   (China)

^b NONE

Author keywords

Germinal center; Immunophenotyping; Lymphoma, large cell, diffuse; Prognosis

Indexed keywords

COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; INTERFERON REGULATORY FACTOR 4; PROTEIN BCL 6;

ARTICLE; B CELL LYMPHOMA; CONTROLLED STUDY; GERMINAL CENTER; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; SURVIVAL RATE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; B-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; FOLLOW-UP STUDIES; GERMINAL CENTER; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON REGULATORY FACTORS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEPRILYSIN; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 35648973827     PISSN: 05295807     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Jaffe ES, Harris NL, Stein H, et al. World Health Organization classification of tumours. Pathology and genetics of tumour of haematopoietic and lymphoid tissue. Lyon: IARC Press, 2001: 171-174.
2. Chinese source
3. Xu Y, McKenna RW, Molberg KH, et al. Clinicopathologic analysis of CD10 + and CD10- diffuse large B-cell lymphoma. Identification of a high-risk subset with coexpression of CD10 and bcl-2. Am J Clin Pathol, 2001, 116(2):183-190.
4. Lopez-Guillermo A, Colomo L, Jimenez M, et al. Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. J Clin Oncol, 2005, 23(12): 2797-2804.
5. Dogan A, Bagdi E, Munson P, et al. CD10 and BCL-6 expression in paraffin sections of normal lymphoid tissue and B-cell lymphomas. Am J Surg Pathol, 2000, 24(6): 846-852.
6. Cutrona G, Leanza N, Ulivi M, et al. Expression of CD10 by human T cells that undergo apoptosis both in vitro and in vivo. Blood, 1999, 94(9): 3067-3076.
7. Cutrona G, Tasso P, Dono M, et al. CD10 is a marker for cycling cells with propensity to apoptosis in childhood ALL. Br J Cancer, 2002, 86(11): 1776-1785.
8. Borgne A, Meijer L. Sequential dephosphorylation of p34 (cdc2) on Thr-14 and Tyr-15 at the prophase/metaphase transition. J Biol Chem, 1996, 271(44): 27847-27854.
9. Ohshima K, Kawasaki C, Muta H, et al. CD10 and Bcl10 expression in diffuse large B-cell lymphoma: CD10 is a marker of improved prognosis. Histopathology, 2001, 39(2): 156-162.
10. Uherova P, Ross CW, Schnitzer B, et al. The clinical significance of CD10 antigen expression in diffuse large B-cell lymphoma. Am J Clin Pathol, 2001,115(4): 582-588.
11. Takeshita M, Iwashita A, Kurihara K, et al. Histologic and immunohistologic findings and prognosis of 40 cases of gastric large B-cell lymphoma. Am J Surg Pathol, 2000, 24(12): 1641-1649.
12. Go JH, Yang WI, Ree HJ. CD10 expression in primary intestinal large B-cell lymphomas: its clinical significance. Arch Pathol Lab Med, 2002, 126(8): 956-960.
13. Chang CC, Ye BH, Chaganti RS, et al. BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci U S A, 1996, 93(14): 6947-6952.
14. Falini B, Mason DY. Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry. Blood, 2002, 99(2): 409-426.
15. Bai M, Agnantis NJ, Skyrlas A, et al. Increased expression of the bcl6 and CD10 proteins is associated with increased apoptosis and proliferation in diffuse large B-cell lymphomas. Mod Pathol, 2003, 16(5): 471-480.
16. Tang TT, Dowbenko D, Jackson A, et al. The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor. J Biol Chem, 2002, 277(16): 14255-14265.
17. Yamochi T, Kaneita Y, Akiyama T, et al. Adenovirus-mediated high expression of BCL-6 in CV-1 cells induces apoptotic cell death accompanied by down-regulation of BCL-2 and BCL-X (L). Oncogene, 1999, 18(2): 487-494.
18. Colomo L, Lopez-Guillermo A, Perales M, et al. Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma. Blood, 2003, 101 (1): 78-84.
19. Muris JJ, Meijer CJ, Vos W, et al. Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma. J Pathol, 2006, 208(5): 714-723.
20. Mamane Y, Heylbroeck C, Genin P, et al. Interferon regulatory factors: the next generation. Gene, 1999, 237(1): 1-14.
21. Falini B, Fizzotti M, Pucciarini A, et al. A monoclonal antibody (MUM1p) detects expression of the MUM1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells. Blood, 2000, 95(6): 2084-2092.
22. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature, 2000, 403(6769): 503-511.
23. Wang CY, Mayo MW, Korneluk RG, et al. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and C-IAP2 to suppress caspase-8 activation. Science, 1998, 281 (5383): 1680-1683.
24. Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-x(L). Mol Cell Biol, 2000, 20(8): 2687-2695.
25. Piva R, Gianferretti P, Ciucci A, et al. 15-Deoxy-δ-12, 14-prostaglandin J2 induces apoptosis in human malignant B cells: an effect associated with inhibition of NF-κB activity and downregulation of antiapoptotic proteins. Blood, 2005, 105(4): 1750-1758.
26. Lam LT, Davis RE, Pierce J, et al. Small molecule inhibitors of IκB kinase are selectively toxic for subgroups of diffuse large B cell lymphoma defined by gene expression profiling. Clin Cancer Res, 2005, 11(1): 2840.
27. Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood, 2004, 103(1): 275-282.
28. Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma. Am J Surg Pathol, 2004, 28(4): 464-470.
29. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma. N Engl J Med, 2002, 346(25): 1937-1947.
30. Bai M, Skyrlas A, Agnantis NJ, et al. Diffuse large B-cell lymphomas with germinal center B-cell-like differentiation immunophenotypic profile are associated with high apoptotic index, high expression of the proapoptotic proteins bax, bak and bid and low expression of the antiapoptotic protein bcl-xl. Mod Pathol, 2004, 17(7): 847-856.
31. Lossos IS. Molecular pathogenesis of diffuse large B-cell lymphoma. J Clin Oncol, 2005, 23(26): 6351-6357.
32. [No authors listed] A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med, 1993, 329 (14): 987-994.